Urology Medical News about prostate cancer

Your Unread Messages

See All

Tracy Hampton, PhD

Clinical Trial Watch

Transplant + Vaccine Therapy Benefits High-Risk Leukemia Patients

Roberta Buell, MBA
HIPAA Breaches Must Be Reported Soon

Dorothy J. Schirf, MD

Technology Advances

Circulating Breast Cancer Cells Validated as Index of Metastases

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Enzyme inhibitor effective against refractory prostate cancer
Urology Times, 11/04/09

Kuznar W – Previous clinical trials have shown that specific inhibition of CYP17 is safe and has antitumor activity in up to 70% of castrate patients with advanced prostate cancer who were resistant to endocrine therapies. The phase II study reported here included 47 patients in whom androgen deprivation therapy had failed. All had had prior docetaxel (Taxotere) chemotherapy. They received abiraterone acetate orally, 1,000mg/day in 28–day cycles. Stable doses of glucocorticoids were allowed.

<< Previous
Degradable and drug-eluting stents: Mixed results

Next >>
Urologists prepare for enforcement of Red Flags Rule